ALZA Corp. will expand its U.S. sales force from fewer than 100 to a total of approximately 360 sales representatives, the Palo Alto, CA-based company announced in July.
ALZA Corp. will expand its U.S. sales force from fewer than 100 to a total of approximately 360 sales representatives, the Palo Alto, CA-based company announced in July.
"We are adding significant strength to our sales organization in both urology and oncology because we believe our existing portfolio, as well as products under late development, such as Ditropan® XL and DUROS⢠leuprolide, will benefit greatly from increased exposure to prescribing physicians," said Ernest Mario, the company's chairman and CEO.
The bigger sales force will be divided into two specialty groups. One will be focused exclusively on the promotion of oncology products to oncologists and the other will be dedicated to promoting urology products to urologists and high-prescribing primary care physicians.
The bulk of the new hires will promote ALZA's urology product line, which includes Elmiron® (pentosan polysulfate), Ditropan® (oxybutynin chloride) and Testoderm® TTS (Testosterone Transdermal System). They will also promote Ditropan® XL, if the FDA grants the product in development marketing clearance.
Seventy-five of the new urology hires will come from Menlo Park, CA-based VIVUS Inc., which markets Muse® (alprostadil) for erectile dysfunction, ALZA reported.
The former VIVUS sales reps will continue to promote Muse for VIVUS until the end of 1998 before focusing solely on ALZA products, according to the agreement between the two companies.
Under a separate agreement, ALZA will also hire 150 contract sales reps from Yardsley, PA-based Innovex Inc. to detail urology products to primary care physicians. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.